NCT01251133View on ClinicalTrials.gov

Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study

PHASE3CompletedINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Infectious Disease by Haemophilus Influenzae Type b

Interventions

BIOLOGICAL

LBVH0101 (Hib vaccine)

0.5mL

BIOLOGICAL

Hiberix™ Vaccine

0.5mL

Trial Locations (1)

Unknown

Korea University Ansan Hospital, Ansan

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY